Cephalon Announces FDA Advisory Committee Recommendation Against Approval of an Expanded Label for FENTORA

Cephalon Conference Call Invitation

Cephalon Reports Strong First Quarter Earnings

Cephalon Appoints Gerald J. Pappert as General Counsel

Cephalon Notified of Generic Fentanyl Buccal Tablet Filing

Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain

Cephalon Quarterly Conference Call Invitation

Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia

FDA Accepts TREANDA(R) New Drug Application for the Treatment of Relapsed Indolent Non-Hodgkin's Lymphoma

Data from Two Pivotal Trials of AMRIX, a New Once-Daily Extended-Release Muscle Relaxant, Presented at the American Academy of Pain Medicine Meeting

Cephalon Statement on Federal Trade Commission Action Regarding PROVIGIL Patent Settlements

Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance

Cephalon General Counsel John E. Osborn to Resign Position

Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application

Cephalon's EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain

Cephalon Quarterly Conference Call Invitation

Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available

Cephalon to Present at the 26th Annual JP Morgan Healthcare Conference